These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 37171335)
1. Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients. Tang YC; Yang CS; Liang MX; Zhang Y; Liu Y; Zou SH; Shi SF Medicine (Baltimore); 2023 May; 102(19):e33719. PubMed ID: 37171335 [TBL] [Abstract][Full Text] [Related]
2. A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma. Liu L; Liu J; Deng X; Tu L; Zhao Z; Xie C; Yang L BMC Cancer; 2022 Jun; 22(1):715. PubMed ID: 35768804 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of RNA editing profiles in lung adenocarcinoma. Shi S; Chen S; Wang M; Guo B; He Y; Chen H Front Genet; 2023; 14():1084869. PubMed ID: 36999050 [No Abstract] [Full Text] [Related]
4. Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma. Pan J; Gu X; Luo J; Qian X; Gao Q; Li T; Ye L; Li C Front Cell Dev Biol; 2022; 10():1073688. PubMed ID: 36531956 [TBL] [Abstract][Full Text] [Related]
5. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients. Wan J; Chen S; Zhang A; Liu Y; Zhang Y; Li Q; Yu Z; Wan Y; Yang L; Wang Q Front Oncol; 2022; 12():861439. PubMed ID: 35494026 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
8. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P Front Oncol; 2023; 13():972558. PubMed ID: 37064115 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465 [TBL] [Abstract][Full Text] [Related]
11. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database. Hu J; Wang L; Li L; Wang Y; Bi J BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874 [TBL] [Abstract][Full Text] [Related]
12. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer. Chen F; Wang Q; Zhou Y BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397 [TBL] [Abstract][Full Text] [Related]
13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
14. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402 [TBL] [Abstract][Full Text] [Related]
15. Construction of Pyroptosis-Related Prognostic and Immune Infiltration Signature in Bladder Cancer. Du X; Zhao X; Tang Y; Tang W Dis Markers; 2022; 2022():6429993. PubMed ID: 36569221 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970 [TBL] [Abstract][Full Text] [Related]
17. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H Front Immunol; 2022; 13():916800. PubMed ID: 35860239 [TBL] [Abstract][Full Text] [Related]
18. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Lu H; Wu J; Liang L; Wang X; Cai H Front Immunol; 2022; 13():803355. PubMed ID: 35154117 [TBL] [Abstract][Full Text] [Related]
19. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis. Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201 [TBL] [Abstract][Full Text] [Related]
20. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma. Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y Front Immunol; 2022; 13():965469. PubMed ID: 36090967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]